Brief: Hanall Biopharma Reports Second Quarter 2022 Results And Provides Business Update
29/07/2022 13:08
July 29 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA REPORTS SECOND QUARTER 2022 RESULTS AND
PROVIDES BUSINESS UPDATE
* HANALL BIOPHARMA CO LTD - Q2 2022 RECORDS REVENUES OF KRW
26.2
BILLION, A 12% GROWTH FROM SAME PERIOD LAST YEAR
* HANALL BIOPHARMA CO LTD - QTRLY OPERATING INCOME WAS 682
MILLION
WON, A 56.6% DECREASE, COMPARED TO SAME PERIOD LAST YEAR
Source text for Eikon: ID:nPn3FH7Xca
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies